Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology von Verheijen, Remy B., Yu, Huixin, Schellens, Jan H.M., Beijnen, Jos H., Steeghs, Neeltje, Huitema, Alwin D.R.

Volltext

Upfront Genotyping of DPYD2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis von Deenen, Maarten J, Meulendijks, Didier, Cats, Annemieke, Sechterberger, Marjolein K, Severens, Johan L, Boot, Henk, Smits, Paul H, Rosing, Hilde, Mandigers, Caroline M P W, Soesan, Marcel, Beijnen, Jos H, Schellens, Jan H M

Volltext

Concise Drug Review: Azacitidine and Decitabine von Derissen, Ellen J.B., Beijnen, Jos H., Schellens, Jan H.M.

Volltext

Fixed Dosing of Monoclonal Antibodies in Oncology von Hendrikx, Jeroen J.M.A., Haanen, John B.A.G., Voest, Emile E., Schellens, Jan H.M., Huitema, Alwin D.R., Beijnen, Jos H.

Volltext

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies von Keizer, Ron J., Huitema, Alwin D. R., Schellens, Jan H. M., Beijnen, Jos H.

Volltext

Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets von Yu, Huixin, Steeghs, Neeltje, Nijenhuis, Cynthia M., Schellens, Jan H. M., Beijnen, Jos H., Huitema, Alwin D. R.

Volltext

Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine von Groenland, Stefanie L., Mathijssen, Ron H. J., Beijnen, Jos H., Huitema, Alwin D. R., Steeghs, Neeltje

Volltext

Variability in bioavailability of small molecular tyrosine kinase inhibitors von Herbrink, Maikel, Nuijen, Bastiaan, Schellens, Jan H.M, Beijnen, Jos H

Volltext

Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2 von de Gooijer, Mark C., de Vries, Nienke A., Buckle, Tessa, Buil, Levi C.M., Beijnen, Jos H., Boogerd, Willem, van Tellingen, Olaf

Volltext

Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of... von Meulendijks, Didier, PharmD, Henricks, Linda M, PharmD, Sonke, Gabe S, MD, Deenen, Maarten J, PhD, Froehlich, Tanja K, PhD, Amstutz, Ursula, PhD, Largiadèr, Carlo R, Prof, Jennings, Barbara A, PhD, Marinaki, Anthony M, PhD, Sanderson, Jeremy D, MD, Kleibl, Zdenek, PhD, Kleiblova, Petra, PhD, Schwab, Matthias, Prof, Zanger, Ulrich M, Prof, Palles, Claire, PhD, Tomlinson, Ian, Prof, Gross, Eva, PhD, van Kuilenburg, André B P, PhD, Punt, Cornelis J A, Prof, Koopman, Miriam, MD, Beijnen, Jos H, Prof, Cats, Annemieke, MD, Schellens, Jan H M, Prof

Volltext

Improving Safety of Fluoropyrimidine Chemotherapy by Individualizing Treatment Based on Dihydropyrimidine Dehydrogenase Activity – Ready for Clinical Practice? von Meulendijks, Didier, Cats, Annemieke, Beijnen, Jos H, Schellens, Jan H.M

Volltext

Mesenchymal Stem Cells Induce Resistance to Chemotherapy through the Release of Platinum-Induced Fatty Acids von Roodhart, Jeanine M.L., Daenen, Laura G.M., Stigter, Edwin C.A., Prins, Henk-Jan, Gerrits, Johan, Houthuijzen, Julia M., Gerritsen, Marije G., Schipper, Henk S., Backer, Marieke J.G., van Amersfoort, Miranda, Vermaat, Joost S.P., Moerer, Petra, Ishihara, Kenji, Kalkhoven, Eric, Beijnen, Jos H., Derksen, Patrick W.B., Medema, Rene H., Martens, Anton C., Brenkman, Arjan B., Voest, Emile E.

Volltext

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing von Verheijen, Remy B., Beijnen, Jos H., Schellens, Jan H. M., Huitema, Alwin D. R., Steeghs, Neeltje

Volltext

Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid von Pluim, Dick, Ros, Willeke, van Bussel, Mark T.J., Brandsma, Dieta, Beijnen, Jos H., Schellens, Jan H.M.

Volltext

Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges von Brummelen, Emilie M.J., Ros, Willeke, Wolbink, Gertjan, Beijnen, Jos H., Schellens, Jan H.M.

Volltext

Bevacizumab von Kazazi‐Hyseni, Filis, Beijnen, Jos H., Schellens, Jan H. M.

Volltext

Increasing Failure of Miltefosine in the Treatment of Kala-azar in Nepal and the Potential Role of Parasite Drug Resistance, Reinfection, or Noncompliance von Rijal, Suman, Ostyn, Bart, Uranw, Surendra, Rai, Keshav, Bhattarai, Narayan Raj, Dorlo, Thomas P. C., Beijnen, Jos H., Vanaerschot, Manu, Decuypere, Saskia, Dhakal, Subodh S., Lal Das, Murari, Karki, Prahlad, Singh, Rupa, Boelaert, Marleen, Dujardin, Jean-Claude

Volltext

Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) in... von Chuan Tang, Seng, Nguyen, Luan N., Sparidans, Rolf W., Wagenaar, Els, Beijnen, Jos H., Schinkel, Alfred H.

Volltext

Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel – a review von de Weger, Vincent A, Beijnen, Jos H, Schellens, Jan H.M

Volltext

Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients von Vermunt, Marit A. C., van Nuland, Merel, van der Heijden, Lisa T., Rosing, Hilde, Beijnen, Jos. H., Bergman, Andries M.

Volltext